Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

A weak day of trading...
Thu, 26 Feb Closing

The Indian markets languished in the red throughout the trading session today on the back of persistent selling pressure across index heavyweights. There was no respite in the final trading hour either and the indices closed well below the dotted line. The BSE-Sensex closed lower by about 261 points, while the NSE-Nifty ended lower by about 83 points. Losses were largely seen in banking, auto and pharma stocks. The BSE Mid Cap index and the BSE Small Cap index were not spared either and closed lower by around 1% each.

Asian stocks ended the day on a mixed note, while stocks in Europe were also trading mixed. The rupee was trading at Rs 61.77 to the dollar at the time of writing.

Pharma stocks closed weak today with the key losers being Sun Pharma, Cipla and Glenmark Pharma. As per a leading business daily, Glenmark has received USFDA approval for launching Trandolapril & Verapamil Hydrochloride (HCl) Extended Release Tablets. This is the generic version of AbbVie Inc's patented drug TARKA. The drug is indicated for the treatment of hypertension. According to IMS Health, the annual sales of the drug stood at US$ 23.5 m for the twelve months ended December 2014. It must be noted that Glenmark's revenues from the US business had slowed down this fiscal and the main reason for this has been the lack of product approvals. Currently, the company has 95 products which are distributed in the US market and it has 74 ANDAs pending approval with the USFDA. Thus, the revenue visibility is there and depends on how fast it gets approvals for these from the US regulator.

Paint stocks also closed in the red today with the key losers being Asian Paints, Berger Paints and Kansai Nerolac. As per a leading business daily, Asian Paints is looking to set up an integrated paints manufacturing plant in either Karnataka or Andhra Pradesh. Reportedly, the company is in negotiations with the respective state governments and the location will be decided based on the availability of land, regulatory approvals and other factors. The rationale behind the move is to cater to the demand in the southern and eastern parts of the country. The approximate investment for setting up the plant with capacity of 6 lakh kilolitre per annum has been pegged at Rs 23 bn over a period of 5 to 7 years.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "A weak day of trading...". Click here!

  

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 8, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS